Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1770 • 2019 ACR/ARP Annual Meeting
Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation
Chrong-Reen Wang¹, Shih-Yao Chen ¹, Yu-Chi Chou ², Chao-Liang Wu ³, Yu-Ting Lo ¹ and Ai-Li Shiau ⁴, ¹National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ²Genomics Research Center, Academia Sinica, Taipei, Taiwan (Republic of China), ³National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China), ⁴National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China)
Background/Purpose: Long non-coding RNAs (lncRNAs) participate in the rheumatoid arthritis (RA) pathogenesis. The aim of this study was to examine the lncRNA H19 and HOTAIR…
Abstract Number: 2249 • 2019 ACR/ARP Annual Meeting
Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment
Aniket Kawatkar¹, ¹Kaiser Permanente Southern California, Pasadena, CA
Background/Purpose: Rheumatoid arthritis (RA) exerts multifaceted burden through medical expenditures, productivity losses, disability, and intangible costs of pain, fatigue, and loss of functional capacity. Patient…
Abstract Number: 2771 • 2019 ACR/ARP Annual Meeting
A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate
Amee Sonigra ¹, Hendrik Nel ², Nishta Ramnoruth ², Meghna Talekar ², Joanne Tesiram ³, Frederik Stuurman ⁴, Lavinia Proctor ⁵, Helen Roberts ⁶, Robin Thurmond ⁷, Phillip Vecchio ³, Ian Gourley ⁸, Mark Rigby ⁹, Nathan Felix ¹⁰, Stephane Becart ¹¹, Kim Campbell ¹² and Ranjeny Thomas², ¹Princess Alexandra Hospital, Woolloongabba, Queensland, Australia, ²University of Queensland, Woolloongabba, Australia, ³Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Centre for Human Drug Research, Leiden, Netherlands, ⁵Dendright, Woolloongabba, Australia, ⁶Dendright, Woolloongabba, Queensland, Australia, ⁷Janssen Research & Development, La Jolla, CA, ⁸Janssen Research & Development, Springhouse, ⁹Janssen Research & Development, La Jolla, ¹⁰Janssen R&D, Spring House, PA, ¹¹Janssen R&D, La Jolla, CA, ¹²Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Antigen-specific immunological tolerance strategies leverage the natural process of antigen presentation by dendritic cells (DCs) to regulate pathogenic T cells and B cells. We…
Abstract Number: 38 • 2019 ACR/ARP Annual Meeting
Autophagy Receptor Optineurin in Synovial Fibroblasts Plays a Protective Role Against Joint Destruction in Rheumatoid Arthritis
Wen Shi Lee¹, Masaru Kato ¹, Eri Sugawara ¹, Michihiro Kono ¹, Yuki Kudo ², Michihito Kono ³, Yuichiro Fujieda ¹, Toshiyuki Bohgaki ¹, Olga Amengual ¹, Kenji Oku ¹, Shinsuke Yasuda ¹ and Tatsuya Atsumi ⁴, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁴Hokkaido University, Sapporo, Japan
Background/Purpose: Joint destructions progress throughout the course of rheumatoid arthritis (RA) without complete remission. Optineurin (OPTN) is an autophagy receptor with multiple functions related to…
Abstract Number: 517 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Mark Genovese¹, Kurt de Vlam ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, Iyabode Tiamiyu ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, David Walker ⁶, Tsutomu Takeuchi ⁷ and Kenneth Kalunian ⁸, ¹Stanford University, Stanford, CA, ²Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Northumbria Healthcare, Northumbria, United Kingdom, ⁷Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁸Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA
Background/Purpose: There is an unmet medical need to treat RA in patients who have failed prior biologic DMARD treatments (biologic DMARD inadequate response; bDMARD-IR), some…
Abstract Number: 928 • 2019 ACR/ARP Annual Meeting
Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks
Ronald van Vollenhoven¹, Tsutomu Takeuchi ², Aileen Pangan ³, Alan Friedman ³, Su Chen ³, Maureen Rischmueller ⁴, Ricardo Blanco ⁵, Ricardo Machado Xavier ⁶ and Vibeke Strand ⁷, ¹Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie Inc., North Chicago, ⁴Department of Rheumatology, The Queen Elizabeth Hospital and University of Adelaide, South Australia, Australia, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁶Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, was efficacious as monotherapy upto 24 weeks (wks) in MTX-naive patients (pts) with active RA.1 To assess safety and efficacy…
Abstract Number: 1332 • 2019 ACR/ARP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization
Sergio Schwartzman¹, Aaron Broadwell ², Alan Kivitz ³, Shawn Black ⁴, Stephen Xu ⁵ and Shelly Kafka ⁶, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, RI, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 1772 • 2019 ACR/ARP Annual Meeting
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Arisa Yaekura¹, Kanta Morii ², Yuto Oketani ³, Ikumi Okumura ², Kenta Kaneshiro ⁴, Kohsuke Yoshida ², Yoshiko Kawasaki ⁵, Nao Shibanuma ⁵, Yoshitada Sakai ⁶ and Akira Hashiramoto ², ¹Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ³Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, ⁵Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁶Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of…
Abstract Number: 2279 • 2019 ACR/ARP Annual Meeting
Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study
Isabell Haase¹, Susanna Spaethling-Mestekemper ², Ralph Brinks ¹, Matthias Schneider ³ and Rebecca Fischer-Betz ³, ¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Rheumapraxis, Munich, Germany, ³Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
Background/Purpose: Women with active Rheumatoid Arthritis (RA) are more prone to relapses and complications during pregnancy. The potential risks of disease activation and treatment during…
Abstract Number: 2848 • 2019 ACR/ARP Annual Meeting
Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)
Stefano Alivernini¹, Barbara Tolusso ¹, Marco Gessi ², Maria Rita Gigante ¹, Luca Petricca ¹, Clara Di Mario ³, Simone Perniola ¹, Anna Laura Fedele ¹, Giusy Peluso ⁴, Laura Bui ², Annunziata Capacci ¹, Francesco Federico ², Gianfranco Ferraccioli ³ and Elisa Gremese ¹, ¹Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Institute of Rheumatology - Università Cattolica del Sacro Cuore, Rome, Italy, ⁴Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy, Italy
Background/Purpose: Ultrasound (US)-guided minimally-invasive Synovial Tissue (ST) biopsy is a well tolerated procedure for basic and translational studies on chronic inflammatory joint diseases as Rheumatoid…
Abstract Number: 44 • 2019 ACR/ARP Annual Meeting
Validation of New Genes Identified in a Molecular Bayesian Network of Rheumatoid Arthritis Synovitis
Teresina Laragione¹, Carolyn Harris ¹, Wenhui Wang ¹, Jun Zhu ¹ and Percio Gulko ¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: We have previously identified new key regulators of Rheumatoid arthritis (RA) synovial pathology using a systems biology approach that combined RA gene expression datasets,…
Abstract Number: 518 • 2019 ACR/ARP Annual Meeting
Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
Mark Genovese¹, Bernard Combe ², Stephen Hall ³, Andrea Rubbert-Roth ⁴, Sheng Zhong ⁵, Sebastian Meerwein ⁶, Aileen Pangan ⁷ and Roy Fleischmann ⁸, ¹Stanford University, Stanford, CA, ²CHU Montpellier, Montpellier University, Montpellier, France, ³Monash University and Emeritus Research, Melbourne, Australia, ⁴Kantonsspital St. Gallen, St Gallen, Switzerland, ⁵AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁶AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) and inadequate response or intolerance to bDMARDs, treatment with upadacitinib (UPA), a JAK1-selective inhibitor resulted in…
Abstract Number: 977 • 2019 ACR/ARP Annual Meeting
Conditional Deletion of MKL1 Inhibits Osteoclast Formation and Bone Erosions in Collagen Induced Arthritis Mice
Wenfeng Tan¹, Aishu Luo ¹, Yong Xu ², Shiyu Lin ³, Miaojia Zhang ⁴ and Fang Wang ³, ¹the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (People's Republic), ²Nanjing Medical University, NANJING, China (People's Republic), ³the First Affiliated Hospital of Nanjing Medical University, Nanjing, ⁴the First Affiliated Hospital of Nanjing Medical University, Najing, China (People's Republic)
Background/Purpose: Excessively osteoclasts (OCs) activation play an essential role in bone erosions in rheumatoid arthritis (RA). Thus, controlling OCs would be an effective strategy to…
Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk ², Orit Schieir ³, Marie-France Valois ⁴, Susan J. Bartlett ⁵, Louis Bessette ⁶, Gilles Boire ⁷, Carol Hitchon ⁸, Edward Keystone ⁹, Janet Pope ¹⁰, Carter Thorne ¹¹, Diane Tin ¹² and Glen Hazlewood ¹, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York City, NY, ³University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ⁴McGill University, Montreal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷Sherbrooke University, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Western University, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Canada
Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
Abstract Number: 1774 • 2019 ACR/ARP Annual Meeting
Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis
Izumi Kurata¹, Isao Matsumoto ¹, Natsuko Mikami ¹, Ayako Ohyama ¹, Atsumu Osada ¹, Yuya Kondo ¹, Hiroto Tsuboi ¹ and Takayuki Sumida ¹, ¹Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Recently, IL-23-Th17 cells axis and hyposialylation of antibodies were proved to be linked to experimental and rheumatoid arthritis. However it remains uncertain how Tfh,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.